SGYP Share Price

Open 5.90 Change Price %
High 5.93 1 Day -0.15 -2.54
Low 5.53 1 Week -0.72 -11.11
Close 5.76 1 Month -0.01 -0.17
Volume 6139873 1 Year 1.81 45.82
52 Week High 6.97
52 Week Low 2.50
SGYP Important Levels
Resistance 2 6.13
Resistance 1 5.98
Pivot 5.74
Support 1 5.54
Support 2 5.39
NASDAQ USA Most Active Stocks
ASTI 0.01 0.00%
QCOM 54.88 -12.72%
QCOM 54.88 -12.72%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
EDMC 0.02 100.00%
CPSL 0.10 66.67%
LOCM 0.09 50.00%
ACFN 0.30 30.43%
LTRE 2.85 29.55%
WRES 0.09 28.57%
QKLS 0.14 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP)

SGYP Technical Analysis 3
As on 23rd Jan 2017 SGYP Share Price closed @ 5.76 and we RECOMMEND Buy for LONG-TERM with Stoploss of 4.41 & Buy for SHORT-TERM with Stoploss of 5.56 we also expect STOCK to react on Following IMPORTANT LEVELS.
SGYP Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
SGYP Other Details
Segment EQ
Market Capital 240850608.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.synergypharma.com
SGYP Address
SGYP
420 Lexington Avenue
Suite 2012
New York, NY 10170
United States
Phone: 212-297-0020
Fax: 212-297-0019
Interactive Technical Analysis Chart Synergy Pharmaceuticals, Inc. ( SGYP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Synergy Pharmaceuticals, Inc.
SGYP Business Profile
Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company�s lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C). It is also developing SP-333, the second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis (UC). The Company�s active pharmaceutical ingredients (APIs) and the final formulated drug products are manufactured for it by third party contractors. As of December 31, 2011, the Company was developing plecanatide, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. Plecanatide is an agonist of GC-C receptor.